Intra-Cellular Therapies Inc (ITCI)
85.24
+1.24
(+1.48%)
USD |
NASDAQ |
Dec 24, 16:00
Intra-Cellular Therapies Enterprise Value: 7.899B for Dec. 23, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc | 208.30B |
| NovaBay Pharmaceuticals Inc | 1.805M |
| Palatin Technologies Inc | 16.58M |
| iBio Inc | 11.49M |
| Theriva Biologics Inc | -12.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.32M |
| Revenue (Quarterly) | 175.16M |
| Total Expenses (Quarterly) | 214.01M |
| EPS Diluted (Quarterly) | -0.25 |
| Gross Profit Margin (Quarterly) | 91.26% |
| Profit Margin (Quarterly) | -15.03% |
| Earnings Yield | -1.02% |
| Normalized Earnings Yield | -1.020 |